Selective inhibitors for the human immunoproteasome LMP7 (β5i) subunit over the
constitutive proteasome hold promise for the treatment of autoimmune and inflammatory …

Cells of hematopoietic origin express high levels of the immunoproteasome, a cytokine‐
inducible proteasome variant comprising the proteolytic subunits LMP2 (β1i), MECL‐1 (β2i) …

Proteasomes are broadly expressed key components of the ubiquitin-dependent protein
degradation pathway containing catalytically active subunits (β1, β2, and β5). LMP7 (β5i) is …

Building upon the success of bortezomib (VELCADE) and carfilzomib (KYPROLIS), the
design of a next generation of inhibitors targeting specific subunits within the …

Background and Purpose Multicatalytic endopeptidase complex‐like‐1 (β2i), low molecular
mass polypeptide (LMP) 2 (β1i) and LMP7 (β5i) are the proteolytically active subunits of the …

The immunoproteasome, having been linked to neurodegenerative diseases and
hematological cancers, has been shown to play an important role in MHC class I antigen …

The pan-proteasome inhibitor bortezomib demonstrated clinical efficacy in off-label trials of
Systemic Lupus Erythematosus. One potential mechanism of this clinical benefit is from the …

The immunoproteasome is a highly efficient proteolytic machinery derived from the
constitutive proteasome and is abundantly expressed in immune cells. The …

The immunoproteasome, a special class of the proteasome, is mainly expressed in cells of
haematopoietic origin. Additionally, during inflammation, the immunoproteasome is induced …

Treatment of cells with interferon-γ leads to the replacement of the constitutive catalytic
proteasome subunits β1, β2, and β5 by the inducible subunits LMP2 (β1i), MECL-1 (β2i) …